June 30, 2022

Eyal Rubin Senior Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. 2 University Plaza, Suite 100 Hackensack, NJ 07601

BioTherapeutics, Inc.

2022

Re: Protalix

Form 10-K for the

Filed March 31,

File No. 001-33357

Dear Mr. Rubin:

Year Ended December 31, 2021

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding

any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance

Office of Life Sciences